AstraZeneca stock falls after FDA panel votes against new cancer drug
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
ORIGINAL SOURCE →via CNBC Top News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] [Editorial] Creating a smoke-free generation
- [FINANCE] Wingtech posts $1.3 billion loss and faces Shanghai delisting as Nexperia audit collapses — 57% of company's assets can't be verified
- [FINANCE] Futures Waver After Stocks Notch Best Month Since 2020; Apple Earnings | Bloomberg Brief 5/1/2026
- [FINANCE] NOV Q1 Earnings Miss Estimates, Revenues Beat, Decrease Y/Y - Zacks Investment Research
- [FINANCE] J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
- [FINANCE] Bill Ackman’s IPO debut delivers a harsh surprise - thestreet.com